Generex Biotech's Oral-lyn Granted Special Access Authorization by Health Canada
-
Font Size:
Generex Biotechnology (GNBT) quietly released an 8K SEC filing on May 1st. In this "Current Report" they note:
Generex Biotechnology Corporation (the "Company") has received Special Access Programme authorization from the Therapeutic Products Directorate of Health Canada for a patient-specific, physician-supervised treatment of Type-1 Diabetes Mellitus with Generex Oral-lyn™, the Company's proprietary oral insulin spray product. Health Canada's Special Access Programme [SAP] provides access to non-marketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable.
The filing states that a Type 1 patient will be allowed access to Oral-lyn. Her Doctor will record her therapuetic response to Oral-lyn and alert the Director. Investors in Generex hope that positve results may lead to an expansion of the program.
With this development, Generex Oral-lyn
is continuing with its positive momentum at a time the inhalable
sector is in decline due the discontinuation of development of
inhalable insulin devices by Eli Lilly (LLY) and Novo Nordisk
(NVO) and the lung fuction
decline and more recent lung cancer concerns raised by Pfizer (PFE) and
Nektar's (NKTR) Exubera. These hightened pulmonary safety concerns
have brought strong doubt on the efforts of Mannkind (MNKD) in
developing it's own inhalable insulin device. Only Generex's Oral-lyn
is a fine mist liquid spray where all absobtion takes place in the
inner lining of the buccal cavity with no deposition into the
lungs.
What this Special Access Programme [SAP] Authorization from Health Canada illustrates is that current treatment for this Type 1 patient have either failed, were unsuitable, or are unavailable. It is interesting to note that this SAP prgram is allowing the patients Doctor to prescribe Oral-lyn to fill an unspecified and unmet need. This SAP is evidence that current standard insulin injectables, pens or pumps have failed to help this patient. Through this special program, the patients doctor specifically turned to Generex Oral-lyn and Health Canada approved the treatment.
In one SEC filing, we may find evidence not only of Oral-lyn's superiority vs inhalable insulin, but potentially of it's superiority vs current approved treatment options for a specific Type 1 subgroup. This is encouraging news for Generex and their shareholders, as the microcap biotech continues with recruitment in North America for Oral-lyn's worldwide Phase III trial.
Disclosure: Long
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
-
Editor's Picks
-
Most Popular
- The Nature of a Crowded Trade: This Time It's Housing
- American Express Calls Investment Banks' Bluff
- Japan: Recession-Bound As Exports Slow?
- iShares MSCI Mexico: Surprising Strength South of the Border
- A Fed Rate Hike Won't Solve the Current Crisis
- Understanding Metastorm's IPO as an Investment Opportunity
- Full list of Editor's Picks »
- Three Stocks To Be Held To Infinity and Beyond »
- As WaMu, Wachovia Ready Earnings, Comparisons to Wells, USB Are Telling »
- Wall Street Breakfast: Must-Know News »
- Steve Jobs' Health: A Red Herring »
- Financials: How - And When - We Reached the Bottom »
- Four Long-Term Winners Selling at Deep Discounts »
- Apple F3Q08 (Qtr End 6/28/08) Earnings Call Transcript »
- Earnings Preview: Washington Mutual »
- The Agriculture Boom Goes Bust »
- Crazy Dividends »
- Apple's a Buy Under $150 »
-
Long Ideas
-
Short Ideas
-
Cramer's Picks
- Potash Corp. Earns $2.82, a 220% Increase
- Mechel Drops 20% on Putin's Comments
- Auto Retailers' Ability to Pay Debt - What It Means
- Three Conservative Growth Industrial Picks: Adminstaff, Carlisle Companies and Illinois Tool Works
- Wait for August FFIEC Call Reports Before Taking a Long Position in Banks
- Now's the Time to Buy Something
- 3Com Corp.: Undervalued by Half
- Wachovia CEO's Insider Buying Is Another Indication of a Bottom
- Consumer Staple Stocks Are Not Always Safe Haven Investments
- The Long Case for Abbott Laboratories
- Full list of Long Ideas »
- Collateral Damage From the War on Shorts
- Is the Gold Uptrend Over?
- Response to Raymond James' Q3 Conference Call
- eBay is a Not Com - Cramer's Lightning Round (7/23/08)
- Get True Religion - Cramer's Lightning Round (7/22/08)
- Principal Financial Group Vulnerable to Commercial Real Estate Softening?
- Increases in Shorting, Only for Some
- Is a Ban on Short Financial ETFs on the Horizon?
- Is There a More Efficient Shorting Tactic?
- Short Oil as a Long Investment
- Full list of Short Ideas »
- eBay is a Not Com - Cramer's Lightning Round (7/23/08)
- Buy Costco, Get Sirius - Cramer's Stop Trading! (7/23/08)
- Soup Target; Cramer's Mad Money (7/22/08)
- Get True Religion - Cramer's Lightning Round (7/22/08)
- Copper Down Low - Cramer's Stop Trading! (7/22/08)
- Banks Hit Bottom – Cramer’s Mad Money (7/21/08)
- Ends In X - Cramer's Stop Trading! (7/21/08)
- Great American Companies – Cramer’s Lightning Round (7/21/08)
- Market Rotation Bolsters Financials - Fast Money Recap (7/18/08)
- For Everything, Wind - Stop Trading! (7/17/08)
- Full list of Cramers Picks »
Most Popular Feeds
-
ETFs
-
US Market
-
Long Ideas
-
Alt. Energy
- Full list of feeds »
Hedge Fund Jobs
Job Seekers:
- Search jobs by category
- Get job alerts by email or live feed
- Apply online
Employers
- See all recruitment options
- Get applications online or by email



This article has 7 comments:
d
www.cmaj.ca/cgi/conten...
...nothing changes the FACT that the bioavailability of insulin via oralyn is only about 5-7%...in other words, the same quantity of insulin via oralyn per DAY would last 16 - 20 DAYS if given via injection...moreover, the patients would STILL require injections since oralyn is short acting and virtually ALL patients require some form of long acting insulin...and if they're afraid of needles there are needle-free injection systems available -- e.g. medi-jector...GNBT claims to have been selling oralyn in Ecuador for over a year and a half now but have yet to report a single PENNY of revenues there!...GNBT is NOTHING but a bad Canadian joke that is run by a former real estate agent.
d
"These matters raise substantial doubt about its ability to continue as a going concern."
...you figure it out!
Well, thanks for the feed back. GNBT is up over a dollar again today, with a 52 week high of $2.14. I wonder if it could run up again, even temporarily, for a nice pop. It seems to move up and down a fair amount on any new that makes the major wires.
"...nothing changes the FACT that the bioavailability of insulin via oralyn is only about 5-7%...in other words, the same quantity of insulin via oralyn per DAY would last 16 - 20 DAYS if given via injection...moreover, the patients would STILL require injections since oralyn is short acting and virtually ALL patients require some form of long acting insulin...and if they're afraid of needles there are needle-free injection systems available -- e.g. medi-jector"